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Dear Editor, 
We read with interest the manuscript from Martínez-Cardús and colleagues,1 which defines 
methylation heterogeneity, both inter-patient (IPH) and intra-tumoral (ITH), using multiregional 
sampling in colorectal cancer (CRC). The authors show that samples will cluster according to patient-
of-origin rather than site-of-sampling. This observation, where only small variations in molecular 
profiles are found at different tumoral regions, is in agreement with our recent transcriptional-based 
CRC profiling using multiregional sampling of central tumor and invasive front(IF).2 
The authors demonstrate that metastatic tissue displays a higher epigenetic similarity to the inner 
tract surface (TS) than IF. This is an intriguing finding; one might expect that the IF, containing 
actively invasive cells giving rise to the metastatic lesion, would share similar traits with metastatic 
tissue. Their finding suggests that invasion and micro-metastatic disease occur at an early stage. This 
is particularly relevant given the increasing stage I population being detected due to bowel screening 
worldwide. As a result of screening, we are for the first time detecting patients with the most 
aggressive disease, not at stage IV, but while they are loco-regional, presenting a key challenge for 
identifying patients with the highest risk of metastatic relapse at this stage. Data presented here 
may inform patient stratification and provide an additional prognostic tool for clinical decision-
making in aggressive early-stage disease.  
Conversely, the metastatic-TS similarity could also be explained using the phenotypic plasticity 
model,3 involving transient epithelial-to-mesenchymal transition (EMT). Interpreting the data 
presented here using this model suggests that the IF will display an increased diversity of epigenetic 
changes indicative of an ongoing EMT, supported by the high IF diversity noted by the authors. This 
signaling is reversed during mesenchymal-to-epithelial transition at the metastatic site. Transient 
EMT signaling shift of the IF could explain the similarity of the metastatic site to the relatively non-
invasive TS.  
Clinical relevance of epigenetic heterogeneity was tested and tumor stage was identified as an 
independent prognostic factor; therefore subsequent analyses were limited to microsatellite stable 
loco-regional stage I/II/III disease (n=50). Using Cox proportional hazard regression, relapse-free 
survival remained an independent prognostic factor. While removal of stage IV tumors is clearly 
warranted and pooling of stage II/III is widely used when undertaking analysis of this type, we have 
concerns relating to the pooling of stage I cases (5-year survival rate >93%), with more advanced 
stage III tumors, (5 year survival rate 64%, ~50% for stage IIIC). A small numerical imbalance between 
stage I and stage III cases, and associated relapse-risk, could confound clinical interpretation, even 
with the appropriate adjusted multivariate model employed by the authors. Additionally, IF type, 
either expansive or infiltrative, which displays a prognostic trend in the cohort, may confound 
survival between the identified methylation subtypes. These factors become more pertinent when 
undertaking stratification in a small pre-filtered cohort of 50 cases. 
Although the authors have accounted for tumor/stromal ratio using H&E assessment, we and others 
have shown that subtle changes in particular cell lineages can influence transcriptomic profiles and 
have prognostic consequences.2,4,5 H&E staining provides a general assessment of different cellular 
components in each intra-tumoral region, but cannot account for precise changes in specialized 
tumor/stroma/immune lineages without the use of digital pathology combined with 
single/multiplexed biomarker staining. Immune population estimates can be made from methylation 
data alone,6 or in combination with transcriptomics, allowing in silico cell-specific enumeration.7  
Addition of in situ or in silico profiling for tumor/stromal populations would reinforce the general 
histology assessment and allow extended interpretation of the epigenetic biology underpinning the 
findings.  
The data presented demonstrate that methylation patterns with the majority of probesets are 
unaltered across different regional tumor architecture, remaining imprinted according to patient-of-
origin. The clinical relevance remains unanswered, as interpretation of methylation-based prognostic 
signatures are ultimately dependent on defined signaling pathways or in some cases individual 
genes.8 When prognostic classification of methylation is distilled to this level of granularity, the 
subtle changes observed at different regions may result in misclassification, similar to the issues we 
reported for transcriptional classifiers based on stromal-derived genes.2 This is most relevant in 
prospective stratification of patients using colonoscopy or biopsy tissue, where the region-of-origin 
of the sample from within the three-dimensional tumor architecture is unknown. Testing of clinically 
informative signatures for their robustness following potentially confounding multi-regional 
sampling is required. 
Overall, this report provides additional support for the role of transcriptional and epigenetic changes 
in early neoplastic development. Generation of a classifier of aggressive early-invasive disease, 
based on comprehensive biological interrogation, has the potential to immediately inform the 
management of CRC at the earliest disease stage. 
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